Bachem Holding AG BANB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CHF 83.35
- Day Range
- CHF 83.20–85.30
- 52-Week Range
- CHF 48.52–86.00
- Bid/Ask
- CHF 82.35 / CHF 85.00
- Shares Outstanding
- 74.94M
- Market Cap
- CHF 6.30B
- Volume/Avg
- 59,510 / 100,817
Key Statistics
- Price/Earnings (Normalized)
- 45.98
- Price/Sales
- 8.92
- Dividend Yield (Trailing)
- 1.07%
- Dividend Yield (Forward)
- 1.07%
- Dividend Payment Schedule
- May
- Total Yield
- 1.11%
Company Profile
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,725
- Website
- https://www.bachem.com
Valuation
|
Metric
|
BANB
|
|---|---|
Price/Earnings (Normalized) | 45.98 |
Price/Book Value | 4.37 |
Price/Sales | 8.92 |
Price/Cash Flow | 20.61 |
Price/Earnings
BANB
Financial Strength
|
Metric
|
BANB
|
|---|---|
Quick Ratio | 0.49 |
Current Ratio | 1.60 |
Interest Coverage | 152.40 |
Quick Ratio
BANB
Profitability
|
Metric
|
BANB
|
|---|---|
Return on Assets (Normalized) | 6.93% |
Return on Equity (Normalized) | 10.34% |
Return on Invested Capital (Normalized) | 9.66% |
Return on Assets
BANB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%SDRhh | LOCK|$@<& | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?&vJsn | LOCK|#<Wz | $84B | |||
| Moderna Inc
MRNA
| LOCK|#<#R$<Y | LOCK|xd | $83B | |||
| argenx SE ADR
ARGX
| LOCK|&^$Tq< | LOCK|@b< | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|BQ<^?^l | LOCK|Hn | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|NVvLm# | LOCK|%$Vx | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@lDk#m# | LOCK|wW>nm | $29B | |||
| Incyte Corp
INCY
| LOCK|CwwpSk | LOCK|B& | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Gwn^HFF | LOCK|r< | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|c?>^^w@ | LOCK|%> | $14B |
United States